Cytokine and chemokine profiles in neuromyelitis optica: significance of interleukin-6

Abstract

Background: Neuromyelitis optica (NMO) is assumed to be immunologically distinct from multiple sclerosis (MS). Adequate studies about cytokines and chemokines in NMO have been lacking.

Objective: To investigate the contribution of cytokines/chemokines in the pathogenesis of NMO.

Methods: We measured 27 cytokines/chemokines and Th17 cell-associated cytokines in the cerebrospinal fluid (CSF) of 31 NMO, 29 MS and 18 other non-inflammatory neurological disorders patients. The serum levels of some cytokines/ chemokines were also measured. The correlations between clinical characteristics/laboratory findings and levels of cytokines/chemokines in NMO were examined.

Results: The CSF levels of interleukin (IL)-1 receptor antagonist, IL-6, IL-8, IL-13 and granulocyte colony-stimulating factor were significantly increased in NMO, while IL-9, fibroblast growth factor-basic, granulocyte macrophage colony-stimulating factor, macrophage inflammatory protein-1-beta and tumor necrosis factor-alpha were increased in MS. IL-10 and interferon-gamma-inducible protein-10 were elevated in NMO and MS. In serum analyses, only the IL-6 level showed significant elevation in NMO. The CSF IL-6 level had a significant correlation with the CSF glial fibrillary acidic protein level and CSF cells, and a weak correlation with anti-aquaporin-4 antibody titers.

Conclusions: Different immunological status and pathophysiologies exist between NMO and MS, and IL-6 may play important roles in the pathogenesis of NMO.

Keywords

chemokine cytokine glial fibrillary acidic protein immunohistochemical staining interleukin-6 multiple sclerosis neuromyelitis optica

Get full access to this article

View all access options for this article.

References

Wingerchuk DM , Hogancamp WF , O’Brien PC and Weinshenker BG The clinical course of neuromyelitis optica (Devic’s syndrome). Neurology 1999; 53: 1107 1114.

Wingerchuk DM , Lennon VA , Lucchinetti CF , Pittock SJ and Weinshenker BG The spectrum of neuromyelitis optica. Lancet Neurol 2007; 6: 805 815 .

Lennon VA , Kryzer TJ , Pittock SJ , Verkman AS and Hinson SR IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005; 202: 473 477.

Takahashi T. , Fujihara K. , Nakashima I. , Misu T. , Miyazawa I. , Nakamura M. , et al. Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre. Brain 2007; 130: 1235 1243.

Roemer SF , Parisi JE , Lennon VA , Benarroch EE , Lassmann H. , Bruck W. , et al. Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain 2007; 130: 1194 1205.

Misu T. , Fujihara K. , Kakita A. , Konno H. , Nakamura M. , Watanabe S. , et al. Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis. Brain 2007; 130: 1224 1234.

Ito S. , Mori M. , Makino T. , Hayakawa S. and Kuwabara S. ‘‘Cloud-like enhancement’’ is a magnetic resonance imaging abnormality specific to neuromyelitis optica. Ann Neurol 2009; 66: 425 428.

Matsuoka T. , Matsushita T. , Kawano Y. , Osoegawa M. , Ochi H. , Ishizu T. , et al. Heterogeneity of aquaporin-4 autoimmunity and spinal cord lesions in multiple sclerosis in Japanese. Brain 2007 ; 130: 1206 1223.

Uzawa A. , Mori M. , Hayakawa S. , Masuda S. and Kuwabara S. Different responses to interferon beta-1b treatment in patients with neuromyelitis optica and multiple sclerosis. Eur J Neurol 2010; 17: 672 676.

10.

Lucchinetti CF , Mandler RN , McGavern D. , Bruck W. , Gleich G. , Ransohoff RM , et al. A role for humoral mechanisms in the pathogenesis of Devic’s neuromyelitis optica. Brain 2002; 125: 1450 1461.

11.

Luster AD Chemokines-chemotactic cytokines that mediate inflammation. N Engl J Med 1998; 338: 436 445.

12.

Sharief MK and Hentges R. Association between tumor necrosis factor-alpha and disease progression in patients with multiple sclerosis. N Engl J Med 1991; 325: 467 472.

13.

Sharief MK and Thompson EJ Correlation of interleukin-2 and soluble interleukin-2 receptor with clinical activity of multiple sclerosis. J Neurol Neurosurg Psychiatry 1993; 56: 169 174.

14.

Link J. , Soderstrom M. , Olsson T. , Hojeberg B. , Ljungdahl A. and Link H. Increased transforming growth factor-beta, interleukin-4, and interferon-gamma in multiple sclerosis. Ann Neurol 1994; 36: 379 386.

15.

van Boxel-Dezaire AH , Hoff SC , van Oosten BW , Verweij CL , Drager AM , Ader HJ , et al. Decreased interleukin-10 and increased interleukin-12p40 mRNA are associated with disease activity and characterize different disease stages in multiple sclerosis. Ann Neurol 1999; 45: 695 703.

16.

Franciotta D. , Martino G. , Zardini E. , Furlan R. , Bergamaschi R. , Andreoni L. , et al. Serum and CSF levels of MCP-1 and IP-10 in multiple sclerosis patients with acute and stable disease and undergoing immunomodulatory therapies. J Neuroimmunol 2001; 115: 192 198.

17.

Narikawa K. , Misu T. , Fujihara K. , Nakashima I. , Sato S. and Itoyama Y. CSF chemokine levels in relapsing neuromyelitis optica and multiple sclerosis. J Neuroimmunol 2004; 149: 182 186.

18.

Ishizu T. , Osoegawa M. , Mei FJ , Kikuchi H. , Tanaka M. , Takakura Y. , et al. Intrathecal activation of the IL-17/ IL-8 axis in opticospinal multiple sclerosis. Brain 2005; 128: 988 1002.

19.

Matusevicius D. , Kivisäkk P. , He B. , Kostulas N. , Ozenci V. , Fredrikson S. , et al. Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis. Mult Scler 1999; 5: 101 104.

20.

Lock C. , Hermans G. , Pedotti R. , Brendolan A. , Schadt E. , Garren H. , et al. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med 2002; 8: 500 508.

21.

Tanaka M. , Matsushita T. , Tateishi T. , Ochi H. , Kawano Y. , Mei FJ , et al. Distinct CSF cytokine/chemokine profiles in atopic myelitis and other causes of myelitis. Neurology 2008 ; 71: 974 981.

22.

Yanagawa K. , Kawachi I. , Toyoshima Y. , Yokoseki A. , Arakawa M. , Hasegawa A. , et al. Pathologic and immunologic profiles of a limited form of neuromyelitis optica with myelitis. Neurology 2009; 73: 1628 1637.

23.

Uzawa A. , Mori M. , Ito M. , Uchida T. , Hayakawa S. , Masuda S. , et al. Markedly increased CSF interleukin-6 levels in neuromyelitis optica, but not in multiple sclerosis. J Neurol 2009; 256: 2082 2084.

24.

Wingerchuk DM , Lennon VA , Pittock SJ , Lucchinetti CF and Weinshenker BG Revised diagnostic criteria for neuromyelitis optica. Neurology 2006; 66: 1485 1489.

25.

Hayakawa S. , Mori M. , Okuta A. , Kamegawa A. , Fujiyoshi Y. , Mitsuoka K. , et al. Neuromyelitis optica and anti-aquaporin-4 antibodies measured by an enzyme-linked immunosorbent assay. J Neuroimmunol 2008; 196: 181 187.

26.

McDonald WI , Compston A. , Edan G. , Goodkin D. , Hartung HP , Lublin FD , et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121 127.

27.

Correale J. and Fiol M. Activation of humoral immunity and eosinophils in neuromyelitis optica. Neurology 2004; 63: 2363 2370.

28.

Weaver CT , Hatton RD , Mangan PR and Harrington LE IL-17 family cytokines and the expanding diversity of effector T cell lineages . Annu Rev Immunol 2007; 25: 821 852 .

29.

Onishi RM and Gaffen SL Interleukin-17 and its target genes: mechanisms of interleukin-17 function in disease. Immunology 2010; 129: 311 321.

30.

Wang GY , Sun B. , Kong QF , Zhang Y. , Li R. , Wang JH , et al. IL-17 eliminates the therapeutic effects of myelin basic protein-induced nasal tolerance in experimental autoimmune encephalomyelitis by activating IL-6. Scand J Immunol 2008; 68: 89 97 .

31.

Iwakura Y. and Ishigame H. The IL-23/IL-17 axis in inflammation. J Clin Invest 2006; 116: 1218 1222.

32.

Fossiez F. , Djossou O. , Chomarat P. , Flores-Romo L. , Ait-Yahia S. , Maat C. , et al. T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J Exp Med 1996 ; 183: 2593 2603.

33.

Van Wagoner NJ , Oh JW , Repovic P. and Benveniste EN Interleukin-6 (IL-6) production by astrocytes: autocrine regulation by IL-6 and the soluble IL-6 receptor. J Neurosci 1999; 19: 5236 5244.

34.

Misu T. , Takano R. , Fujihara KT , Takahashi T. , Sato S. and Itoyama Y. Marked increase in cerebrospinal fluid glial fibrillar acidic protein in neuromyelitis optica: an astrocytic damage marker. J Neurol Neurosurg Psychiatry 2009; 80: 575 577.

35.

Lee HK , Seo IA , Suh DJ , Hong JI , Yoo YH and Park HT Interleukin-6 is required for the early induction of glial fibrillary acidic protein in Schwann cells during Wallerian degeneration. J Neurochem 2009; 108: 776 786.

36.

Jarius S. , Aboul-Enein F. , Waters P. , Kuenz B. , Hauser A. , Berger T. , et al. Antibody to aquaporin-4 in the long-term course of neuromyelitis optica. Brain 2008; 131: 3072 3080.

37.

Quintana A. , Muller M. , Frausto RF , Ramos R. , Getts DR , Sanz E. , et al. Site-specific production of IL-6 in the central nervous system retargets and enhances the inflammatory response in experimental autoimmune encephalomyelitis. J Immunol 2009; 183: 2079 2088.

38.

Eugster HP , Frei K. , Kopf M. , Lassmann H. and Fontana A. IL-6-deficient mice resist myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis. Eur J Immunol 1998; 28: 2178 2187.

39.

Linker RA , Lühder F. , Kallen KJ , Lee DH , Engelhardt B. , Rose-John S. , et al. IL-6 transsignalling modulates the early effector phase of EAE and targets the blood brain barrier. J Neuroimmunol 2008; 205: 64 72.

40.

Kaplin AI , Deshpande DM , Scott E. , Krishnan C. , Carmen JS , Shats I. , et al. IL-6 induces regionally selective spinal cord injury in patients with the neuroinflammatory disorder transverse myelitis. J Clin Invest 2005; 115: 2731 2741.